Dr. Mikhael on the Promise of Bispecific Antibodies in Multiple Myeloma

Video

Joseph Mikhael, MD, discusses the promise of bispecific antibodies in multiple myeloma.

Joseph Mikhael, MD, professor, Applied Cancer Research and Drug Discovery Division, Translational Genomics Research Institute, affiliate, City of Hope Cancer Center, chief medical officer, International Myeloma Foundation, discusses the promise of bispecific antibodies in multiple myeloma.

Novel therapeutic choices are always needed in multiple myeloma because patients may be ineligible for certain treatments for various reasons, such as renal insufficiency or comorbidities, Mikhael says.

Bispecific antibodies are a promising emerging therapeutic class in multiple myeloma. These agents could offer an off-the-shelf T-cell therapy for patients who can’t or don’t want to wait for CAR T-cell therapy manufacturing, Mikhael says. Additionally, bispecific antibodies that engage natural killer cells could emerge with similar efficacy but less risk of cytokine release syndrome vs T-cell therapies.

Finally, bispecific antibodies could have a role as maintenance therapy for patients who obtain a response with CAR T-cell therapy, Mikhael says. As has always been a goal of research in multiple myeloma, the field is continuing to improve treatment by synergizing the activity of different agents, such as CAR T-cell therapy and bispecific antibodies, Mikhael concludes.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD